Merck 2010 Annual Report Download - page 75
Download and view the complete annual report
Please find page 75 of the 2010 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65 -
66 -
67 -
68 -
69 -
70 -
71 -
72 -
73 -
74 -
75 -
76 -
77 -
78 -
79 -
80 -
81 -
82 -
83 -
84 -
85 -
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
-
183
-
184
-
185
-
186
-
187
-
188
-
189
-
190
-
191
-
192
-
193
-
194
-
195
-
196
-
197
-
198
-
199
-
200
-
201
-
202
-
203
-
204
-
205
-
206
-
207
-
208
-
209
-
210
-
211
-
212
-
213
-
214
-
215
-
216
-
217
-
218
-
219
-
220
-
221
-
222
-
223
 |
 |
EUR million 2010 2009 ∆ in %
Total revenues 1,681 929 81
Gross margin 871 434 101
R&D 78 32 141
Operating result 44 106 –59
Exceptional items – 11 –
Free cash flow –4,672 123 –
Underlying free cash flow 263 128 106
ROS in % 2.6 11.5
The division’s ROS amounted to 2.6% compared to 11.5% in 2009. Underlying free cash flow
was EUR 263 million compared to EUR 128 million in 2009.
The realignment of the Chemicals business sector as a result of the acquisition is enabling
Merck to achieve leading positions in high-margin, fast-growing markets, e.g. the biotech
industry. The company is now even less exposed to economic cycles. The steady, resilient
revenue stream from the Merck Millipore division balances the Liquid Crystals business within
Performance Materials and the Pharmaceuticals business sector. Merck Millipore is positioned
globally as a strategic supplier driven by innovation, premium brand products, and competitive
differentiation in increasingly competitive sectors.
With its products for life science research in the pharmaceutical and biotechnology industries
as well as academia, the Bioscience Business Unit accounts for about 20% of the division’s
total revenues. It is focused on offering solutions that help scientists to conduct life science
research easily, efficiently and economically.
The Bioscience Business Unit provides an increasing number of tools and services to support
researchers seeking to understand complex biological systems as well as to identify and charac-
terize new therapeutic targets.
Company 71Management Report Corporate governance Consolidated Financial Statements More information
Merck Millipore